Boosting clinical expertise
26.06.2012 - Swiss Molecular Partners AG (Zurich-Schlieren) has appointed hematologist Lisa Rojkjaer as its new Chief Medical Officer. Rojkjaer, who comes in from German antibody specialist MorphoSys AG, has a track record of 10 years in biopharmaceutical drug development.
She will be heading up all clinical activities at Molecular Partners. Prior to her post as Vice President and Head of Clinical Development at Morphosys, she held a variety of senior positions in clinical development and medical affairs at Novartis and Novo Nordisk.